Stem cell therapy is an exciting area of research that holds tremendous potential for helping chronic pain patients reduce their pain. Rapid advances in this field of medicine are buoying doctors and patients hopes that the exciting therapy could change lives. Advances are being made nearly every day, and as scientists further understand the nature of these cells, even more uses for them are becoming known. If youve ever wondered about how stem cell therapy for pain could help you, these 15 questions delve into how this therapy works and who it could be used for.
Science has a strong interest in stem cells because of their renewing properties and the ability of these cells to develop into any type of tissue in the body of the organism. Researchers believe that they have the potential for immeasurable clinical uses in health. Research is advancing many stem cell based therapies for people who suffer from diseases such as:
Mayo Clinic explains how this therapy works:
Stem cell therapy, also known as regenerative medicine, promotes the reparative response of diseased, dysfunctional or injured tissue using stem cells or their derivativesResearchers grow stem cells in a lab. These stem cells are manipulated to specialize into specific types of cells, such as heart muscle cells, blood cells or nerve cells. The specialized cells can then be implanted into a person.
Stem cell therapy is actually a type of treatment within the larger umbrella of regenerative medicine. Our longer post on regenerative medicine discusses the types of treatments available, including stem cell therapy and platelet-rich plasma injections.
Stem cells are essentially blank canvases that can transform into any type of cell in the human body. Specialized cells like bone cells, liver cells, and heart cells begin as stem cells. The process of the cells transforming from blank slates into specialized cells is called differentiation.
Stem cell therapy is the process of injecting these cells into damaged areas of the body, such as arthritic knees or shoulders. The stem cells then differentiate into damaged tissue, helping to regenerate the entire area.
There are two different types of natural stem cells and one that is genetically reprogrammed within the laboratory. Embryonic stem cells are the most immature and are found within the early stages of a growing embryo, usually after it has been left to develop five to six days. After the egg and sperm have united, the fertilized egg divides and creates stem cells that differentiate into the specialized cells the body requires to function. Many techniques using stem cells for pain therapies no longer rely on these types of stem cells.
The second type of stem cell, found naturally in organisms, is adult stem cells. These are present in developed tissue, such as muscle, skin, bone, brain, and blood. Also called tissue stem cells, they can self-renew and generate one specialized cell type. Under normal circumstances these tissue stem cells, or adult stem cells, will generate the type of cells that make up the organ in which they reside. These cells are used by the body to divide and repair injured areas or regenerate into specialized cells to replace the ones that are dead or damaged.
The third type of stem cells, which are genetically reprogrammed in the laboratory, are induced pluripotent stem cells. After years of stem cell research and development, it was discovered that artificially triggering certain genetic components would prompt different cells to become pluripotent stem cells, which were similar in nature to embryonic stem cells. This helps avoid ethical concerns associated with using human embryonic tissue for research and regenerative medicine.
The following video from an Arizona pain doctor goes into detail about how stem cell therapy for pain works.
There are twomajor types of stem cells: those harvested from adults and those harvested from embryonic tissues.
However, there are other ways to retrieve stem cells that reduce the use of embryonic stem cells, including:
As the Euro Stem Cell organization reports, some of these types of stem cells are more effective than others.
One source of stem cells is human embryos. These cells are called pluripotent stem cells, and theyre very useful to researchers because they can be multiplied indefinitely in the laboratory. Although these cells are often cultivated from embryos that are just a few days old, they can also be taken from fetal tissue thats older than eight weeks, according to the National Institutes of Health (NIH).
The majority of therapeutic stem cells come from adults. Even though embryos are the richest source of stem cells, humans of all ages have stem cells. Stem cells give adults the ability to replace damaged tissue, heal wounds, and grow hair.The patients own adult stem cells are extracted, purified, concentrated, and then injected into the damaged tissue. This process is usually non-surgical and the individual has very little recovery time. Most patients report only some soreness around the site of the injection. Sometimes there is also slight bruising. There have been no reports of serious side effects from treatments using stem cell therapy.
Newer research has given scientists the ability to reprogram specialized adult cells so they essentially return to their original stem cell state. These reprogrammed cells are known as induced pluripotent stem cells. Although this ability exists, scientists arent sure how or if these artificially created stem cells behave differently than other types.
Despite these unknowns, the reprogrammed stem cells are already being used in the development of medicines and helping scientists learn more about specific types of diseases, according to NIH.
Stem cells have many uses, and the full spectrum of their application isnt yet known. One way stem cells are helping researchers is by illuminating the inner workings of various diseases. Stem cells offer scientists the ability to model human disease progression in a laboratory setting.
This is exciting because many studies rely on animals with similar, but not exact, biology to humans. The more scientists can understand about human-specific disease progression, the greater insight they have regarding potential treatments.
For example, one of the earliest uses for stem cells were bone marrow transplants, used to help patients with leukemia or sickle cell anemia heal. This treatment has been used for more than 40 years. In addition, stem cell therapy may be used to treat:
The application of most interest to chronicpatients is likely the emerging field of regenerative medicine, which is the science of helping tissues regenerate. This field examines the potential of stem cells to repair damaged tissue and heal areas of the body bone and potentially organs, too affected by arthritis, diabetes, spinal cord injuries, nerve damage, Parkinsons disease, and more.
Exciting research has also uncovered the potential for stem cells to expand the number of lungs available for transplant. A portion of lungs available for transplant arent used because they become damaged. However, research from the American Physiological Society has found stem cells could help repair the organs and prepare them to save lives.
Other recent researchstories include:
For many of the studies underway, time is needed to fully examine the benefits and potential dangers of this treatment. Another obstacle is obtaining specific types of adult stem cells. Theyre difficult to grow in the laboratory, making it hard to produce the large numbers available for research.
Another potential issue with donor stem cells is the possibility of rejection. The immune system of the recipient could reject the cells, essentially making it difficult for the treatment to work as intended and causing ancillary problems.
Finally, since this is such a new treatment area, some government agencies are calling for more oversight of its use. Others are pushing back, claiming that stem cell therapy provides a new area of treatment for patients who have exhausted all other options.
That being said, even though there are complications and roadblocks to its use, the benefits of stem cell therapy could be huge. As the American Academy of Anti-Aging Medicine notes:
[A]n analysis of the potential benefits of stem cells based therapies indicates that 128 million people in the United States alone may benefit with the largest impact on patients with Cardiovascular disorders (5.5 million), autoimmune disorders (35 million) and diabetes (16 million US patients and more than 217 million worldwide).
Californias Stem Cell Agency gives a great overview of this process, noting:
In order to be approved by the FDA for use in human trials, stem cells must be grown in good manufacturing practice (GMP) conditions. Under GMP standards, a cell line has to be manufactured so that each group of cells is grown in an identical, repeatable, sterile environment. This ensures that each batch of cells has the same properties, and each person getting a stem cell therapy gets an equivalent treatment. Although the FDA hasnt yet issued guidelines for how pluripotent stem cells need to meet GMP standards, achieving this level of consistency could mean knowing the exact identity and quantity of every component involved in growing the cells.
Stem cell therapy is being studied for a number of chronic pain conditions, especiallypain in the:
Stem cell therapy for pain could help reduce the inflammation that results in chronic pain, or it could help to heal regenerative conditions that lead to pain, such as arthritis.
Using stem cell therapy for knee pain is one of the leading areas of research. Stem cell therapy for knees can be provided as stem cell injections or as blood platelet treatments from the body itself (another form of regenerative medicine).These two treatments may help relieve pain associated with:
The leading researchers on stem cell therapy for knee pain claim that it can help patients avoid surgery, with its associated costs and risks.
Since stem cell therapy promises to treat a number of conditions related to degenerative conditions, like arthritis and tendonitis, stem cell therapy may present a great treat option for hip pain related to these causes.
The National Multiple Sclerosis Society is leading the efforts in research, but currently reports the following:
At present, there are no approved stem cell therapies for MS. Larger, longer-term, controlled studies are needed to determine the safety and effectiveness of using stem cells to treat MS. When the results of these and subsequent clinical trials are available, it should be possible to determine what the optimal cells, delivery methods, safety and actual effectiveness of these current experimental therapies might be for different people with MS.
Potentially. One of our sister clinics, Arizona Pain, is participating in a study evaluating the potential of stem cells to reduce back pain related to degenerative disc disease. This progressive condition sometimes results from injury, but other times has no clear cause.
The study is exciting because it involves stem cells harvested from the bone marrow of healthy, young adults, and therefore itdoesnt come with the ethical concerns of embryonic stem cells. So far, the results have been very positive, and a significant number of people who received stem cells for their back pain have experienced reduced discomfort and improved quality of life.
This study is currently in Phase III, which is the phase immediately preceding potential FDA approval. This means it could soon be available to many more patients and potentially covered by insurance, although each insurance companys coverage policy varies.
Absolutely, and the research into this area is very promising. In fact, scientists have recently uncovered the specific type of stem cell most likely to reduce arthritis pain. Theyre special cells that are specifically able to rebuild tissue, bone, and cartilage, potentially offering much relief to osteoarthritis patients.
What other questions do you have regarding stem cell therapy for pain? If youre ready to learn more about using stem cell therapy to treatyour pain, click the button below to find a pain specialist in your area.
See original here:
15 Stem Cell Therapy For Pain Questions, Answered
- Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer -... - November 21st, 2019
- CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia - Business Wire - November 21st, 2019
- Brooks Koepka Withdraws From Presidents Cup Team - The New York Times - November 20th, 2019
- Rational discovery of antimetastatic agents targeting the intrinsically disordered region of MBD2 - Science Advances - November 20th, 2019
- Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected... - November 20th, 2019
- 10 promising developments that can help Alzheimer's patients - ISRAEL21c - November 20th, 2019
- Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology - Business Wire - November 20th, 2019
- Eli Lilly touts $400M manufacturing expansion, 100 new jobs to much fanfare in Indianapolis even though it's been chopping staff - Endpoints News - November 20th, 2019
- Global Stem Cell Therapy for Osteoarthritis Market 2019 Growth Factors, Technological Innovation and Emerging Trends 2024 - News Appear - November 20th, 2019
- Shark Tank Season 11 Episode 8 Everything About Gallant Stem Cell Bank For Dogs As Seen on Shark Tank! Unknown Facts - TheNewsCrunch - November 17th, 2019
- Innovative Biosensor Technology for Stem Cells Leads Way to Treatment of Alzheimers, Parkinsons Diseases - SciTechDaily - November 17th, 2019
- These Israeli Companies Are Finding Innovative Ways To Improve Diabetes Care, Treatment | Health News - NoCamels - Israeli Innovation News - November 17th, 2019
- Cocker spaniel with cancer to receive stem cells from mother living 4,000 miles away - Fox News - November 16th, 2019
- Hip osteoarthritis: 6 ways to treat it - Medical News Today - November 16th, 2019
- Gracell Announces Five Presentations at the Annual Meeting of American Society of Hematology (ASH) - BioSpace - November 16th, 2019
- Leading Alternative Healing Director of Total Health Institute Reviews and Receives 3rd Fellowship in Stem Cell Therapy - Financialbuzz.com - November 16th, 2019
- Broncos Briefs: CB Bryce Callahan headed to surgery to replace bent screw in foot - Longmont Times-Call - November 16th, 2019
- Celgene Receives CHMP Positive Opinion for REVLIMID (lenalidomide) in Combination With Rituximab for the Treatment of Adult Patients With Previously... - November 16th, 2019
- New Cell Therapy Improves Memory and Stops Seizures Following TBI - University Herald - November 16th, 2019
- Stem Cell Therapy Market 2019 Global Industry Growth Analysis, Segmentation, Size, Share, Trend, Future Demand and Leading Players Updates by Forecast... - November 16th, 2019
- The Heart of the Matter: Leveraging Advances in Cardiac Biology to Innovate Gene-Based Therapies for Heart Failure - Physician's Weekly - November 16th, 2019
- Taiwan Announced the Application of Cell Therapy, The Value of The Medical Industry was Improved - Benzinga - November 16th, 2019
- Im grateful for the kindness of strangers in my cancer recovery - The Globe and Mail - November 16th, 2019
- Global Stem Cell Therapy Market Share, Revenue, Business Growth, Demand and Applications Market Research Report to 2029 - Trade Examiner - November 16th, 2019
- Allogene Moves Forward With CAR-T Therapy Pipeline - Seeking Alpha - November 12th, 2019
- Texan Spending Fortune, Hours A Day Trying To Live To At Least 120 Years Old: I Am My Asset - CBS Dallas / Fort Worth - November 12th, 2019
- Heart-warming moment OAP meets mum who saved his life with anonymous stem cell donation after three years of - The Sun - November 12th, 2019
- CytoDyn Receives IRB Approval To Proceed With Compassionate Use Of Leronlimab For Patients With Triple-Negative Breast Cancer - GlobeNewswire - November 12th, 2019
- Editas and Celgene sub Juno are tackling hottest immunotherapy cells - Endpoints News - November 12th, 2019
- Promethera Biosciences Presents Updated Clinical Results at AASLD 2019 for World's First Stem Cell Therapy Trial using HepaStem in Acute-on-Chronic... - November 11th, 2019
- Triple-Drug Induction Therapy Yields Sustained Responses in Multiple Myeloma - Hematology Advisor - November 11th, 2019
- Global cell therapy market is expected to grow with a healthy CAGR over the forecast period from 2019-2025 - Yahoo Finance - November 11th, 2019
- Gary Pesselt: Vitality Healthcare is it worth the cost? - The Union of Grass Valley - November 11th, 2019
- Stem Cell Banking Market to Witness Robust Expansion throughout the Forecast 2017-2023: : Allied Market Research - GuruFocus.com - November 11th, 2019
- Cancer Stem Cells (CSCs) Market 2019 | Industry Size, Trends, Global Growth, Insights and Forecast Research Report 2025 - Business Daily Mirror - November 11th, 2019
- Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 - Weekly Spy - November 11th, 2019
- Ixazomib Extends Survival in Multiple Myeloma for Patients Not Treated With Stem Cell Transplantation - Pharmacy Times - November 10th, 2019
- Phase III trial of Ninlaro as first-line maintenance therapy meets PFS in multiple myeloma - The Cancer Letter - November 10th, 2019
- Roll Over Yamanaka: Meet The Cell Therapy Company Bypassing iPSCs - Scrip - November 10th, 2019
- Tears And Joy This Toddler with Down Syndrome Who Was Battling Leukemia Is Finally Cancer Free - SurvivorNet - November 10th, 2019
- Tales of medical misinformation and misadventures - Stuff.co.nz - November 10th, 2019
- AgeX Therapeutics to Present at Investing in the Age of Longevity Conference - Business Wire - November 10th, 2019
- 'My shock cancer scare and the anonymous German who saved me' - Birmingham Live - November 10th, 2019
- Laura Beil's New Podcast Bad Batch Sheds Light on the World of Unregulated Stem Cell Treatment - D Magazine - November 6th, 2019
- Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting - Business... - November 6th, 2019
- bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition - Financial... - November 6th, 2019
- Three Podcasts to Listen to in November - The New Yorker - November 6th, 2019
- Celularity to Present New Data at the ASH Annual Meeting on Novel Allogeneic, Off the Shelf, Placental Derived CAR T and NK Cell Therapy Programs -... - November 6th, 2019
- 19-28z CAR-T Therapy in Children and Young Adults With Relapsed/Refractory ALL: Promising Early Results - Cancer Therapy Advisor - November 6th, 2019
- Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting -... - November 6th, 2019
- MD Anderson on a Roll with Another Pharma Deal, This Time with Artios and ShangPharma - BioSpace - November 6th, 2019
- Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 Process B for Fanconi Anemia at the 61st American Society of Hematology Annual... - November 6th, 2019
- Dystrogen Therapeutics Announces That Treatment With Dystrophin Expressing Chimeric (DEC) Cells Improves Cardiac Function in Preclinical Duchenne's... - November 6th, 2019
- Transient Wave of Hematopoietic Stem Cell Production in Late Fetuses and Young Adults - Technology Networks - November 6th, 2019
- Three UCLA scientists receive grants totaling more than $18 million - UCLA Newsroom - November 4th, 2019
- Can This Cell Therapy Help Fight the NASH... - Labiotech.eu - November 4th, 2019
- Interview With Chaim Lebovits, CEO Of Brainstorm Cell Therapeutics - Seeking Alpha - November 4th, 2019
- Galera Therapeutics And Amgen In Severe Oral Mucositis - Seeking Alpha - November 4th, 2019
- The Curious Case Of Enochian Biosciences: Value Out Of Thin Air - Price Target $1 - Seeking Alpha - November 4th, 2019
- Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress - BioSpace - November 4th, 2019
- Stem Cell Banking Market Anticipated to Grow at a Significant Pace by 2028 - Weekly Spy - November 4th, 2019
- Stempeutics to receive US patent for Stempeucel - BSI bureau - November 4th, 2019
- How Stem Cells Can Heal The Body - Version Weekly - November 4th, 2019
- Light-activated pancreatic cells produce insulin on demand - New Atlas - November 4th, 2019
- Future Outlook: Animal Stem Cell Therapy Market 2019- 2025| Research Methodologies Offers High Business Outlook growth - Pledge Times - November 4th, 2019
- Surgeon banned over 'quack' procedures and 'reckless disregard' for safety - Sydney Morning Herald - November 3rd, 2019
- Five-year-old leukaemia patient Zachary White spots Nessie on dream-come-true Scotland trip - Extra.ie - November 3rd, 2019
- An Expert Discusses PARP Inhibition, Vaccines and Emerging Therapies in Kidney Cancer - Curetoday.com - November 3rd, 2019
- Leukaemia: what is it, how to spot the warning signs and who is at risk? - The Telegraph - November 3rd, 2019
- Restore your crowning glory with recombinant DNA tech - The New Paper - November 3rd, 2019
- Is blood cancer curable at an early stage? - The Indian Awaaz - November 3rd, 2019
- Stem Cell Therapy: What's Real and What's Not at California's For-Profit Clinics - UCSF News Services - November 2nd, 2019
- The Science Of Stem Cell Research Hits A Snag With Bad Batch - Forbes - November 2nd, 2019
- Mallinckrodt Announces UVADEX (Methoxsalen) Approved in Australia for use with the THERAKOS CELLEX Photopheresis System for Treatment of Chronic Graft... - November 2nd, 2019
- AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November - P&T Community - November 2nd, 2019
- Q&A: Draper's Jenna Balestrini on the future of CAR-T - - pharmaphorum - November 2nd, 2019
- Organ donations: What you can do to help save a life - Calgary Herald - November 2nd, 2019
- Six ways cancer is treated - The Standard - November 2nd, 2019
- Stem cell therapy approved for MS patients in Scotland - HeraldScotland - October 29th, 2019
- Battle brews over how tightly to regulate new cancer treatment - Crain's Detroit Business - October 29th, 2019